Dose escalation study of the HLA-A2-WT1 CD3 bispecific antibody RO7283420 in relapsed/refractory acute myeloid leukemia by Martin Hutchings, Koorosh Korfi, Pau Montesinos, Armando Santoro, Hsin-An Hou, Pilar Martinez-Sanchez, Susana Vives, Sara Galimberti, Tsai-Yun Chen, Marco Frigeni, Sylvain Garciaz, Olga Salamero Garcia, Su-Peng Yeh, Karen Yee, Jordi Esteve, Ashish Bajel, Shaun Fleming, Anne Catherine Bretz, Jan Attig, Min Sun, Sina Nassiri, Tobias Rutishauser, Christian Klein, Y. May Ma, Gabriel Schnetzler, Stephanie Vauleon, Huixin Yu, Teresa Barata, Muriel Richard, Silke Simon, Heather Hinton, Nino Keshelava, Marion Subklewe

Get full text

Safety run-in and part 1 of GIMEMA AML1718: venetoclax combined with FLAI as induction treatment in non–low-risk AML by Giovanni Marconi, Alfonso Piciocchi, Ernesta Audisio, Cristina Papayannidis, Marco Cerrano, Clara Minotti, Francesca Paoloni, Fabio Guolo, Monica Bocchia, Michela Rondoni, Albana Lico, Matteo G. Carrabba, Matteo Giovanni Della Porta, Marco Frigeni, Luisa Giaccone, Germana Beltrami, Chiara Cattaneo, Maria Chiara Di Chio, Bianca Serio, Enrico Crea, Roberto Freilone, Saveria Capria, Antonio Curti, Paola Minetto, Edoardo la Sala, Jacopo Nanni, Beatrice Anna Zannetti, Giorgia Simonetti, Maria Teresa Bochicchio, Giuseppe Saglio, Roberto M. Lemoli, Adriano Venditti, Marco Vignetti, Paola Fazi, Giovanni Martinelli

Get full text